Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06262139 · ClinicalTrials.gov registry record · Phase 1
Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
A Phase 1 study of MRI Scan, sponsored by Songqi Gao.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06262139 is a Phase 1 study of MRI Scan that is actively recruiting participants, run by Songqi Gao. The registered enrollment target is 12 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06262139, a Phase 1 study of MRI Scan, is actively recruiting participants, sponsored by Songqi Gao.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.
Conditions Studied
Interventions
- DRUG MT218 injection
Study Locations (1)
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2024-07-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06262139
The ClinicalTrials.gov registry entry for NCT06262139 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Songqi Gao, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with MRI Scan appearing as the primary indexed condition, and to 1 intervention - of which MT218 injection is the first listed.
NCT06262139 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT06262139 about?
NCT06262139 is a clinical study titled "Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients". This phase 1b open label, dose-escalating investigation study is to evaluate the dose dependent initial efficacy of the use of MT218 injection for biomarker targeted MR molecular imaging (MRMI) of prostate cancer in patients scheduled for radical prostatectomy.
What is the current status of trial NCT06262139?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2024-07-25. Estimated completion is 2026-12.
What conditions does trial NCT06262139 study?
This clinical trial studies the following conditions: MRI Scan.
What interventions are being tested in trial NCT06262139?
The interventions under investigation include: MT218 injection (DRUG).
Who is sponsoring clinical trial NCT06262139?
This trial is sponsored by Songqi Gao, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06262139 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.